Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated dose of metformin alone in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes in patients already being treated with the combination of ertugliflozin and metformin as separate tablets.
METFORMIN HYDROCHLORIDE — GLENMARK PHARMS LTD, approved 2019-11-25 (ANDA212969).
58,064 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.